APPENDIXES - AHRQ Effective Health Care Program

More documents

Recommendations

Info

Appendix D: List of Excluded Studies (continued) 331. Kiel HJ, Wieland WF, Rossler W. Local control of prostate cancer by transrectal HIFUtherapy. Arch Ital Urol Androl. Dec 2000;72(4):313319. No provider characteristics. 332. Kim BS, Lashkari A, Vongtama R, et al. Effect of pelvic lymph node irradiation in salvage therapy for patients with prostate cancer with a biochemical relapse following radical prostatectomy. Clin Prostate Cancer. Sep 2004;3(2):9397. Not eligible exposure. 333. Kim JC, Gerber GS. Should laparoscopy be the standard approach used for pelvic lymph node dissection? Curr Urol Rep. Apr 2001;2(2):171 179. Review. 334. King CR, Presti JC, Jr., Gill H, et al. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes? Int J Radiat Oncol Biol Phys. Jun 1 2004;59(2):341347. Not eligible exposure. 335. Kiriyama I, Ohgaki K, Ohba S, et al. Prostate cancer in patients with Hansen's disease. Int J Urol. Mar 2003;10(3):177179. Not eligible target population. 336. Kish JA. Neoadjuvant androgen ablation in localized carcinoma of the prostate. Cancer Control. MarApr 2001;8(2):155162. Review. 337. Kiyokawa H, Kato H. Radical retropubic prostatectomy through a minimal incision with portless endoscopy: our initial experience. Int J Urol. Jan 2006;13(1):79. No provider characteristics. 338. Klabunde CN, Potosky AL, Harlan LC, et al. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med <strong>Care</strong>. Sep 1998;36(9):13371348. Not eligible outcomes. 339. Klassen AC, Curriero FC, Hong JH, et al. The role of arealevel influences on prostate cancer grade and stage at diagnosis. Preventive Medicine. 2004/9 2004;39(3):441448. Not eligible outcomes. 340. Klee LW, Grmoljez P. Combined radical retropubic prostatectomy and rectal resection. Urology. Oct 1999;54(4):679681. Not eligible exposure. 341. Klein EA. Prostate cancer. J Urol. Jul 1995;154(1):143144. Comment. 342. Klein EA. Radiation therapy versus radical prostatectomy in the PSA era: a urologist's view. Semin Radiat Oncol. Apr 1998;8(2):8794. Review. 343. Klein EA, Kupelian PA, Dreicer R, et al. Locally advanced prostate cancer. Curr Treat Options Oncol. Oct 2001;2(5):403411. Review. 344. Klein EA, Kupelian PA, Tuason L, et al. Initial dissection of the lateral fascia reduces the positive margin rate in radical prostatectomy. Urology. May 1998;51(5):766773. Not eligible exposure. 345. Klutke CG, Tiemann DD, Nadler RB, et al. Antegrade collagen injection for stress incontinence after radical prostatectomy: technique and early results. J Endourol. Jun 1996;10(3):279282. Not eligible exposure. 346. Knight SJ, Nathan DP, Siston AK, et al. Pilot study of a utilitiesbased treatment decision intervention for prostate cancer patients. Clin Prostate Cancer. Sep 2002;1(2):105114. Not eligible exposure. 347. Koch MO. Predicting outcomes after radical prostatectomy. J Urol. Nov 2000;164(5):1601. Comment. 348. Koch MO, Foster RS, Bell B, et al. Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy. J Urol. Sep 2000;164(3 Pt 1):749753. Not eligible exposure. 349. Koch MO, Smith JA, Jr. Influence of patient age and comorbidity on outcome of a collaborative care pathway after radical prostatectomy and cystoprostatectomy. J Urol. May 1996;155(5):16811684. Not eligible exposure. 350. Kochakarn W, RatanaOlarn K, Viseshsindh V. Vesicourethral strictures after radical prostatectomy: review of treatment and outcome. J Med Assoc Thai. Jan 2002;85(1):63 66. Not eligible exposure. 351. Kollermann J, Caprano J, Budde A, et al. Followup of nondetectable prostate carcinoma (pT0) after prolonged PSAmonitored neoadjuvant hormonal therapy followed by radical prostatectomy. Urology. Sep 2003;62(3):476480. Not eligible exposure. 352. Kollermann MW, Pantel K, Enzmann T, et al. Supersensitive PSAmonitored neoadjuvant hormone treatment of clinically localized prostate cancer: effects on positive margins, tumor detection and epithelial cells in bone marrow. Eur Urol. Oct 1998;34(4):318324. Not eligible exposure. 353. Koppie TM, Grossfeld GD, Nudell DM, et al. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol. Jul 2001;166(1):111115. Not eligible exposure. D57
Appendix D: List of Excluded Studies (continued) 354. Korman HJ, Mulholland TL, Huang R. Preservation of fecal continence and bowel function after radical perineal and retropubic prostatectomy: a questionnairebased outcomes study. Prostate Cancer Prostatic Dis. 2004;7(3):249252. Not eligible exposure. 355. Koyanagi T. Assessing a new surgical procedure: an initial step to randomized trial. Int J Clin Oncol. Apr 2003;8(2):124125. Comment. 356. Krahn M, Ritvo P, Irvine J, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med <strong>Care</strong>. Jan 2003;41(1):153164. Not eligible exposure. 357. Krogh J, Jensen JS, Iversen HG, et al. Age as a prognostic variable in patients undergoing transurethral prostatectomy. Scand J Urol Nephrol. 1993;27(2):225229. Not eligible target population. 358. Kuefer R, Hofer MD, Zorn CS, et al. Assessment of a fragment of ecadherin as a serum biomarker with predictive value for prostate cancer. Br J Cancer. Jun 6 2005;92(11):20182023. Not eligible exposure. 359. Kumar V, Toussi H, Marr C, et al. The benefits of radical prostatectomy beyond cancer control in symptomatic men with prostate cancer. BJU Int. Mar 2004;93(4):507509. Not eligible exposure. 360. Kundel Y, Pfeffer R, Lauffer M, et al. Salvage prostatic fossa radiation therapy for biochemical failure after radical prostatectomy: the Sheba experience. Isr Med Assoc J. Jun 2004;6(6):329 331. Not eligible exposure. 361. Kuyu H, Lee WR, Bare R, et al. Recent advances in the treatment of prostate cancer. Ann Oncol. Aug 1999;10(8):891898. Review. 362. Kylmala T, Kaipia A, Matikainen M. Management of prolonged urinary leakage at the urethrovesical anastomosis. Urol Int. 2005;74(4):298300. Case reports. 363. Lacombe L, Maillette A, Meyer F, et al. Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. Int J Cancer. May 20 2001;95(3):135139. Not eligible exposure. 364. LaFontaine P, Chan D, Partin AW, et al. Minilaparotomy radical retropubic prostatectomy: updated technique and results. Semin Urol Oncol. Feb 2000;18(1):1927. Not eligible exposure. 365. Lam JS, Sclar JD, Desai M, et al. Is Hispanic race an important predictor of treatment failure following radical prostatectomy for prostate cancer? J Urol. Nov 2004;172(5 Pt 1):1856 1859. Not eligible exposure. 366. Lance RS, Freidrichs PA, Kane C, et al. A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group. BJU Int. Jan 2001;87(1):6165. Not eligible exposure. 367. Landmann C. Radiation therapy of localized prostate cancer. Ann Urol (Paris). 1994;28(4):207220. Not eligible exposure. 368. Lang GS, Ruckle HC, Hadley HR, et al. One hundred consecutive laparoscopic pelvic lymph node dissections: comparing complications of the first 50 cases to the second 50 cases. Urology. Aug 1994;44(2):221225. Review. 369. Larson TR, Rrobertson DW, Corica A, et al. In vivo interstitial temperature mapping of the human prostate during cryosurgery with correlation to histopathologic outcomes. Urology. Apr 2000;55(4):547552. Not eligible exposure. 370. Lassiter LK, Eisenberger MA. The dilemma of patients with a rising PSA level after definitive local therapy for prostate cancer. Semin Urol Oncol. May 2002;20(2):146154. Not eligible exposure. 371. Laven BA, Alsikafi NF, Yang XJ, et al. Minor modifications in apical dissection of radical retropubic prostatectomy in patients with clinical stage T2 prostate cancer reduce positive surgical margin incidence. Urology. Jan 2004;63(1):9598. Not eligible exposure. 372. Lawrence G, Crawford J. Systemic benefit of local radiation therapy. Int J Radiat Oncol Biol Phys. Dec 1 2003;57(5):15101511; author reply 1511. Comment. 373. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 8531 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. Mar 15 2001;49(4):937946. Not eligible exposure. 374. Lee CT. Re: Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst. May 5 2004;96(9):718719. Comment. 375. Lee CT, Capodieci P, Osman I, et al. Overexpression of the cyclindependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res. May 1999;5(5):977983. Not eligible exposure. D58
Page 1 and 2:
APPENDIXES
Page 3 and 4:
Appendix A: Search Strategy (contin
Page 6 and 7:
Appendix C: Evidence Tables and Fig
Page 8 and 9:
Table C1. Disease specific mortalit
Page 10 and 11:
Table C2. Biochemical progression/r
Page 12 and 13:
Table C2. Biochemical progression/r
Page 14 and 15:
Table C4. Incidence of distant meta
Page 16 and 17:
Figure C2. Diseasespecific surviv
Page 18 and 19:
Table C8. Outcomes after cryosurgic
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Table C10. Comparative effectivenes
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Table C13. Perioperative and pathol
Page 32 and 33:
Figure C4. Comparative studies of t
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Table C17. Clinical outcomes after
Page 44 and 45:
Table C19. Late toxicity outcomes a
Page 46 and 47:
Table C20. Patient outcomes after h
Page 48 and 49:
Table C21. Proton radiation for loc
Page 50 and 51:
Table C23. Adjusted percentage dist
Page 52 and 53:
Table C25. QOL studies of treatment
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Figure C6. Search strategy Database
Page 62 and 63:
Table C27. Quality (% of maximum po
Page 64 and 65:
Table C29. Geographic variations in
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Table C31. Association between hosp
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Table C36. Association between surg
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Table C41. Sampling sources of stud
Page 106 and 107:
Table C43. Association between phys
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Figure C8. Percentage of responses
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Table C44. Variability in managemen
Page 122 and 123:
Table C44. Variability in managemen
Page 124 and 125:
Table C45. Association between prov
Page 126 and 127:
Table C45. Association between prov
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Table C47. Distribution of urologis
Page 134 and 135:
Table C49. Significant geographic d
Page 136 and 137:
Figure C14. Distribution of radiati
Page 138 and 139:
Figure C16. Ratio* of radiation onc
Page 140 and 141:
Page 142 and 143:
Figure C19. Geographic variations i
Page 144 and 145:
Figure C20. Incidence of prostate c
Page 146 and 147:
Page 148 and 149:
Table C55. Incidence of localized p
Page 150 and 151:
Figure C21. Percentage of patients
Page 152 and 153:
Page 154 and 155:
Table C62. Significant variations i
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Figure C29. Length of stay in hospi
Page 166 and 167:
Figure C30. Hospital charges for ra
Page 168 and 169:
Table C73. Geographic differences i
Page 170 and 171:
Figure C31. Mortality from prostate
Page 172 and 173:
Figure C33. Difference in surgery
Page 174 and 175:
Figure C35. Relative risk of surger
Page 176 and 177:
Figure C37. Difference in surgery r
Page 178 and 179:
Figure C39. Difference in surgery r
Page 180 and 181:
Figure C41. Difference in length of
Page 182 and 183:
Figure C43. Difference in rates of
Page 184 and 185:
Table C76. Odds ratio and attributa
Page 186 and 187:
Table C78. Odds ratio of outcomes,
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Appendix D: List of Excluded Studie
Page 198 and 199:
Page 200 and 201:
Page 202 and 203: Appendix D: List of Excluded Studie
Page 272: Appendix D: List of Excluded Studie
Page 275 and 276: Appendix E: Sample Abstraction Form
show all

APPENDIXES - AHRQ Effective Health Care Program

Create successful ePaper yourself

Delete template?

Save as template?